EZH2 is frequently overexpressed or mutated in breast, prostate lung and other cancers, and inhibitors targeting EZH2 are currently being examined as a therapeutic approach to treat these tumors [38, 39, 41]. This evidence concerns the gene EZH2 and cancer.